文献速递流行病学与生物统计临床试验与 GCP

成人肥胖药物治疗疗效与安全性的系统综述与荟萃分析

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
PubMed 文献 · Nat Med · 2025-10-02

该研究通过系统综述与网络荟萃分析,评估多种肥胖管理药物在减重及改善肥胖相关并发症方面的疗效与安全性。共纳入56项随机对照试验、60307例患者,所有药物较安慰剂均显著降低总体重百分比,其中司美格鲁肽和替尔泊肽减重超过10%。不同药物在血糖正常化、2型糖尿病缓解、心血管事件及特定并发症缓解方面效果各异,结果支持个体化选择药物。

要点

  • 所有肥胖管理药物较安慰剂均显著降低总体重百分比(P < 0.0001)。
  • 司美格鲁肽和替尔泊肽减重超过10%。
  • 替尔泊肽和司美格鲁肽可恢复血糖正常、缓解2型糖尿病并减少心衰住院。

核心结论

  • 所有肥胖管理药物较安慰剂均显著降低总体重百分比(P < 0.0001),司美格鲁肽和替尔泊肽减重超过10%。
  • 替尔泊肽和司美格鲁肽可恢复血糖正常、缓解2型糖尿病并减少心衰住院;司美格鲁肽减少主要不良心血管事件并减轻膝骨关节炎疼痛;替尔泊肽缓解阻塞性睡眠呼吸暂停综合征和代谢功能障碍相关脂肪性肝炎。
  • 结果支持个体化选择肥胖管理药物。

研究设计与样本

  • 系统综述与网络荟萃分析,检索Medline和Embase截至2025年1月31日,纳入比较肥胖管理药物与安慰剂/活性对照的成人随机对照试验。
  • 共纳入56项临床试验,涉及60307例患者(肥胖管理药物组32598例,安慰剂组27709例),包括奥利司他(22项)、司美格鲁肽(14项)、利拉鲁肽(11项)、替尔泊肽(6项)、纳曲酮/安非他酮(5项)和芬特明/托吡酯(2项)。

主要发现

  • 所有肥胖管理药物较安慰剂均显著降低总体重百分比(P < 0.0001),司美格鲁肽和替尔泊肽减重超过10%。
  • 替尔泊肽和司美格鲁肽可恢复血糖正常、缓解2型糖尿病并减少心衰住院。
  • 司美格鲁肽减少主要不良心血管事件并减轻膝骨关节炎疼痛;替尔泊肽缓解阻塞性睡眠呼吸暂停综合征和代谢功能障碍相关脂肪性肝炎。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This systematic review and network meta-analysis evaluated the efficacy and safety of obesity management medications (OMMs) in terms of reducing body weight and impact on obesity-related complications. Here a Medline and Embase search was performed up to 31 January 2025 for randomized controlled trials comparing OMMs versus placebo/active comparators in adults. Primary endpoint was percentage of total body weight loss (TBWL%) at the end of the study. Secondary endpoints were TBWL% at 1, 2 and ≥3 years, lipid profile, blood pressure, hemoglobin A1c, fasting plasma glucose, mental health, serious adverse events, quality of life, cardiovascular morbidity and mortality, remission of obesity-related complications and all-cause mortality. Fifty-six clinical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), naltrexone/bupropion (5) and phentermine/topiramate (2)-enrolling 60,307 patients (32,598 OMM and 27,709 placebo). All OMMs showed a significantly greater TBWL% versus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide. Both tirzepatide and semaglutide showed normoglycemia restoration, remission of type 2 diabetes and reduction in hospitalization due to heart failure. Semaglutide was effective in reducing major adverse cardiovascular events and reducing pain in knee osteoarthritis. Tirzepatide was effective in remission of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis. These results support the need to individualize the selection of OMMs.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025. PMID: 41039116. doi:10.1038/s41591-025-03978-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。